6USX

Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer

Summary for 6USX

• Entry DOI: 10.2210/pdb6usx/pdb
• Descriptor: GTPase KRas, GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, ... (5 entities in total)
• Functional Keywords: hydrolase inhibitor, hydrolase, hydrolase-inhibitor complex, hydrolase/inhibitor
• Biological source: Homo sapiens (Human)
• Total number of polymer chains: 2
• Total formula weight: 40669.91

Authors

Vigers, G.P.,Smith, D.J. (deposition date: 2019-10-28, release date: 2020-04-22, Last modification date: 2023-10-11)

• Primary citation: Fell, J.B.,Fischer, J.P.,Baer, B.R.,Blake, J.F.,Bouhana, K.,Briere, D.M.,Brown, K.D.,Burgess, L.E.,Burns, A.C.,Burkard, M.R.,Chiang, H.,Chicarelli, M.J.,Cook, A.W.,Gaudino, J.J.,Hallin, J.,Hanson, L.,Hartley, D.P.,Hicken, E.J.,Hingorani, G.P.,Hinklin, R.J.,Mejia, M.J.,Olson, P.,Otten, J.N.,Rhodes, S.P.,Rodriguez, M.E.,Savechenkov, P.,Smith, D.J.,Sudhakar, N.,Sullivan, F.X.,Tang, T.P.,Vigers, G.P.,Wollenberg, L.,Christensen, J.G.,Marx, M.A.; Identification of the Clinical Development CandidateMRTX849, a Covalent KRASG12CInhibitor for the Treatment of Cancer.; J.Med.Chem., 63:6679-6693, 2020; PubMed: 32250617; DOI: 10.1021/acs.jmedchem.9b02052

Experimental method

X-RAY DIFFRACTION (2.27 Å)